ES2953834T3 - Derivados novedosos de ftalazinona y su procedimiento de fabricación - Google Patents

Derivados novedosos de ftalazinona y su procedimiento de fabricación Download PDF

Info

Publication number
ES2953834T3
ES2953834T3 ES14843941T ES14843941T ES2953834T3 ES 2953834 T3 ES2953834 T3 ES 2953834T3 ES 14843941 T ES14843941 T ES 14843941T ES 14843941 T ES14843941 T ES 14843941T ES 2953834 T3 ES2953834 T3 ES 2953834T3
Authority
ES
Spain
Prior art keywords
mmol
compound
fluoro
carbonyl
phthalazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14843941T
Other languages
English (en)
Spanish (es)
Inventor
Jae-Hoon Kang
Hong-Sub Lee
Yoon-Suk Lee
Joon-Tae Park
Kyung-Mi An
Jin-Ah Jeong
Kyung-Sun Kim
Jeong-Geun Kim
Chang-Hee Hong
Sun-Young Park
Dong-Keun Song
Yong-Don Yun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Idience Co Ltd
Original Assignee
Idience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idience Co Ltd filed Critical Idience Co Ltd
Application granted granted Critical
Publication of ES2953834T3 publication Critical patent/ES2953834T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
ES14843941T 2013-09-13 2014-09-12 Derivados novedosos de ftalazinona y su procedimiento de fabricación Active ES2953834T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20130110170 2013-09-13
KR1020140120152A KR101670126B1 (ko) 2013-09-13 2014-09-11 신규 프탈라지논 유도체 및 그 제조방법
PCT/KR2014/008523 WO2015037939A1 (en) 2013-09-13 2014-09-12 A novel phtalazinone derivatives and manufacturing process thereof

Publications (1)

Publication Number Publication Date
ES2953834T3 true ES2953834T3 (es) 2023-11-16

Family

ID=53024930

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14843941T Active ES2953834T3 (es) 2013-09-13 2014-09-12 Derivados novedosos de ftalazinona y su procedimiento de fabricación

Country Status (25)

Country Link
US (3) US9682973B2 (enExample)
EP (1) EP3030557B1 (enExample)
JP (1) JP6180643B2 (enExample)
KR (1) KR101670126B1 (enExample)
CN (1) CN105793248B (enExample)
AU (1) AU2014319132C1 (enExample)
BR (1) BR112016004979B1 (enExample)
CA (1) CA2923614C (enExample)
DK (1) DK3030557T3 (enExample)
ES (1) ES2953834T3 (enExample)
FI (1) FI3030557T3 (enExample)
HR (1) HRP20230998T1 (enExample)
HU (1) HUE062770T2 (enExample)
IL (1) IL244548B (enExample)
LT (1) LT3030557T (enExample)
MX (1) MX379467B (enExample)
MY (1) MY195343A (enExample)
PL (1) PL3030557T3 (enExample)
PT (1) PT3030557T (enExample)
RS (1) RS64477B1 (enExample)
RU (1) RU2636585C2 (enExample)
SG (1) SG11201600549TA (enExample)
SI (1) SI3030557T1 (enExample)
SM (1) SMT202300268T1 (enExample)
WO (1) WO2015037939A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
WO2019169156A1 (en) 2018-02-28 2019-09-06 The Trustees Of The University Of Pennsylvania Low affinity poly(ad-ribose) polymerase 1 dependent cytotoxic agents
JP7626783B2 (ja) * 2020-04-21 2025-02-07 アイディーエンス カンパニー リミテッド フタラジノン誘導体及びその中間体を調製するプロセス
MY209003A (en) * 2020-04-21 2025-06-16 Idience Co Ltd Crystalline forms of phthalazinone compound
CN115515939B (zh) * 2020-05-08 2024-12-13 谛希诺生物科技有限公司 具有抑制外核苷酸焦磷酸酶-磷酸二酯酶的活性的新型酞嗪衍生物及它们的用途
US12059419B2 (en) * 2020-10-16 2024-08-13 Idience Co., Ltd. Pharmaceutical composition comprising phthalazinone derivatives
WO2022087422A1 (en) * 2020-10-22 2022-04-28 Chulalongkorn University Pyrrolidine-3-carboxamide derivatives and related uses
KR20220125183A (ko) 2021-03-04 2022-09-14 아이디언스 주식회사 Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도
WO2022186649A1 (ko) * 2021-03-04 2022-09-09 아이디언스 주식회사 Parp 억제제에 내성을 가진 환자군의 암 치료제로서의 프탈라지논 유도체의 항암제 용도
KR20240016319A (ko) * 2021-06-02 2024-02-06 아이디언스 주식회사 프탈라지논 유도체를 이용한 장애 치료 방법
WO2023144626A1 (en) * 2022-01-25 2023-08-03 Idience Co., Ltd. Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug
WO2024025389A1 (ko) * 2022-07-29 2024-02-01 아이디언스 주식회사 프탈라지논 유도체의 중간체의 제조방법
CN117229260B (zh) * 2023-11-13 2024-02-27 中国药科大学 DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228960B1 (hu) 2000-10-30 2013-07-29 Kudos Pharm Ltd Ftalazinon-származékok
AU2003229953A1 (en) 2002-04-30 2003-11-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
EP1633724B1 (en) 2003-03-12 2011-05-04 Kudos Pharmaceuticals Limited Phthalazinone derivatives
AU2007266840B2 (en) 2006-05-31 2012-09-20 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrrolo[1,2-A]pyrazin-1(2H)-one and pyrrolo[1,2-D][1,2,4]triazin-1(2H)-one derivatives as inhibitors of poly(ADP-ribose)polymerase(PARP)
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
PL2120579T3 (pl) 2006-12-28 2014-04-30 Abbvie Inc Inhibitory polimerazy poli(ADP-rybozy)
CN101030723A (zh) 2007-04-04 2007-09-05 钟志华 电磁变相发动机
KR101641596B1 (ko) 2007-11-15 2016-07-21 엠에스디 이탈리아 에스.알.엘. Parp 억제제로서의 피리다지논 유도체
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
GB0804755D0 (en) 2008-03-14 2008-04-16 Angeletti P Ist Richerche Bio Therapeutic compounds
US8871765B2 (en) 2010-07-27 2014-10-28 Cadila Healthcare Limited Substituted 4-(4-fluoro-3-(piperazine-1-carbonyl)benzyl)phthalazin-1(2H)-one derivatives as poly (ADP-ribose) polymerase-1 inhibitors
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CN102372698A (zh) 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
US8999985B2 (en) * 2010-12-02 2015-04-07 Shanghai De Novo Pharmatech Co Ltd. Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof
CN102485721B (zh) 2010-12-03 2015-12-09 曹亚 取代的2,3-二氮杂萘酮化合物及其用途
CN103130723B (zh) 2011-11-30 2015-01-14 成都地奥制药集团有限公司 一种多聚(adp-核糖)聚合酶抑制剂
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법

Also Published As

Publication number Publication date
EP3030557A1 (en) 2016-06-15
US20160222003A1 (en) 2016-08-04
KR101670126B1 (ko) 2016-10-27
HRP20230998T1 (hr) 2023-12-08
CA2923614A1 (en) 2015-03-19
CN105793248B (zh) 2019-08-16
MY195343A (en) 2023-01-13
USRE49338E1 (en) 2022-12-20
JP2016534143A (ja) 2016-11-04
LT3030557T (lt) 2023-09-11
EP3030557A4 (en) 2017-03-22
KR20150031196A (ko) 2015-03-23
SG11201600549TA (en) 2016-02-26
US9682973B2 (en) 2017-06-20
US20170182045A1 (en) 2017-06-29
CA2923614C (en) 2017-06-27
WO2015037939A1 (en) 2015-03-19
HUE062770T2 (hu) 2023-12-28
PL3030557T3 (pl) 2023-10-16
PT3030557T (pt) 2023-09-04
MX2016002998A (es) 2016-06-02
IL244548A0 (en) 2016-04-21
SI3030557T1 (sl) 2023-11-30
SMT202300268T1 (it) 2023-09-06
EP3030557B1 (en) 2023-05-31
MX379467B (es) 2025-03-10
AU2014319132A1 (en) 2016-02-11
BR112016004979A2 (pt) 2020-05-12
CN105793248A (zh) 2016-07-20
BR112016004979B1 (pt) 2023-01-10
JP6180643B2 (ja) 2017-08-16
FI3030557T3 (fi) 2023-08-21
DK3030557T3 (da) 2023-09-04
RS64477B1 (sr) 2023-09-29
US9844550B2 (en) 2017-12-19
RU2636585C2 (ru) 2017-11-24
AU2014319132C1 (en) 2020-09-03
IL244548B (en) 2020-10-29
HK1224280A1 (zh) 2017-08-18
RU2016108038A (ru) 2017-09-07
AU2014319132B2 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
ES2953834T3 (es) Derivados novedosos de ftalazinona y su procedimiento de fabricación
US20210363139A1 (en) Cxcr4 inhibitors and uses thereof
US20220356185A1 (en) Mertk degraders and uses thereof
CN106029659A (zh) 谷氨酰胺酶抑制剂
US20240016942A1 (en) Stat degraders and uses thereof
HK1209632A1 (en) Irak inhibitors and uses thereof
TW200806664A (en) Azaindoles useful as inhibitors of janus kinases
CN111386275B (zh) 高活性sting蛋白激动剂
ES2919572T3 (es) Compuestos antiproliferación y usos de los mismos
CN113582974A (zh) 一类作为蛋白降解剂的化合物及其制备方法和医药用途
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
WO2020169058A1 (zh) Pd-l1拮抗剂化合物
CN120981448A (zh) 含氮大环类化合物及其制备方法和应用
TWI901793B (zh) 多功能環二核苷酸及其用途
HK1224280B (zh) 酞嗪酮衍生物及其制备方法
WO2024264070A2 (en) Akt inhibitors
HK40047065B (en) Antiproliferation compounds and uses thereof
HK40047065A (en) Antiproliferation compounds and uses thereof